Bioventus Inc. (BVS) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-14	Dec-31-13
	10-K	10-K	10-K	10-K	10-K	S-1/A	S-1/A
Revenues:
Non-US	57	43	27	35
UNITED STATES	455	388	294	305
Total revenues	512	431	321	340	319
Revenue growth [+]	18.8%	34.2%	-5.6%	6.6%
Non-US	31.2%	57.8%	-21.7%
UNITED STATES	17.5%	32.0%	-3.7%
Cost of goods sold	202	140	95	97	84
Gross profit	310	291	226	243	235
Gross margin	60.6%	67.4%	70.4%	71.4%	73.6%
Selling, general and administrative	333	254	193	198	192
Research and development	26	19	11	11	8
Other operating expenses	-21	-7	-7	-6
EBITDA [+]	18	50	50	62	56
EBITDA growth	-63.8%	-0.4%	-18.8%	11.1%
EBITDA margin	3.6%	11.7%	15.7%	18.3%	17.5%
Depreciation	0	-1	1	4	29
EBITA	18	51	49	58	27
EBITA margin	3.6%	11.8%	15.4%	17.1%	8.3%
Amortization of intangibles	67	35	28	26
EBIT [+]	-49	15	22	32	27
EBIT growth	-416.2%	-29.5%	-31.4%	19.3%
EBIT margin	-9.5%	3.6%	6.8%	9.3%	8.3%
Non-recurring items [+]	202	3	1	1	1
Asset impairment	189				0
Unusual expense					-1
Loss on contingent liability	6	1
Interest expense	18	6	7	15	19
Interest expense	18	6	7	15	19
Other income (expense), net [+]	5	1	2	-6	0
Other	13	-3	4	0	0
Pre-tax income	-264	8	16	10	6
Income taxes	-51	-2	1	2	2
Tax rate	19.1%		7.5%	16.3%	27.2%
Minority interest	-55	-10	-2	-1
Earnings from continuing ops	-159	19	16	13	4
Earnings from discontinued ops				2	17
Net income	-159	19	16	15	-12
Net margin	-31.0%	4.5%	5.1%	4.4%	-3.8%

Basic EPS [+]	($2.59)	$0.43	$17,020.08	$1.27	$1.14
Growth	-706.7%	-100.0%	1336316.1%	11.8%
Diluted EPS [+]	($2.59)	$0.43	$14,722.00	$1.27	$1.14
Growth	-706.7%	-100.0%	1155870.9%	11.8%

Shares outstanding (basic) [+]	61	45	0	10	4
Growth	35.0%	4715915.4%	-100.0%	164.7%
Shares outstanding (diluted) [+]	61	45	0	10	4
Growth	35.0%	4079151.1%	-100.0%	164.7%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.